CPhI Conferences’ Post

The IQVIA Global Markets Insights Team will be at #CPhIJapan in a few weeks! Find us on stand 4D-01 to engage with our experts, discuss your challenges, and explore cutting-edge industry innovations that can help you hit your targets easier and faster. See you there! #GlobalMarketInsights

This is a very significant paper hightlighting the potential of this technology in pharmaceutical industry.

▶️🖱️ Now available on-demand! Watch our webinar featured on Scientist.com on the Applications of Humanized Mice in the Evaluation of Antibody-Drug Conjugates to Treat Autoimmune Diseases! 👉 Click here to watch: https://buff.ly/3yGYTiT This webinar features our Director of Scientific Engagement, Dr. Jun Wang, and BioRay Pharmaceutical's President, Dr. Gang Chen. Key topics include: ☑️ Advantages of using humanized mouse models to evaluate ADCs ☑️ Applications of humanized mice to evaluate ADCs in autoimmune disease models ☑️ The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADCTM) #adcs #antibodydrugconjugates #autoimmune #mousemodels https://buff.ly/3yGYTiT

If you missed the live webinar, you can now watch the recording! #autoimmunemodels

🌟Early bird deadline approaching | 4th International Conference on Polymyxins🌟 ISAC is proud to support the "4th International Conference on Polymyxins: Polymyxins in the era of CROs - opportunities and challenges". 8 - 10 October 2024 Suzhou, China The early bird registration deadline has been extended to 15 August 2024 - don't miss this opportunity to connect with likeminded colleagues. Join us to delve into the latest advancements across all major facets of the polymyxin class of antibiotics. Polymyxins are a last-line therapeutic option for treating life-threatening infections caused by Gram-negative 'superbugs,' including the WHO priority pathogens Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. Since the 3rd International Conference on Polymyxins in 2018 (Madrid, Spain), significant progress has been made in the clinical use and pharmacology of polymyxins, particularly the first scientifically-based dosing recommendations, understanding the mode of action, and addressing the challenges of the resistance and toxicity. The conference will feature cutting-edge presentations by globally renowned clinicians and scientists. This interdisciplinary conference promises enlightening discussions, innovative presentations, and valuable networking opportunities with clinicians, researchers and pharmaceutical companies. Together, we will exchange ideas in the frontiers of polymyxins and pave the way for future collaborations to expedite the improvement of clinical practice and scientific discovery. Register now⬇ https://lnkd.in/e-7htmCf #polymyxins #healthcare #infectiousdisease #clinicalmicro #Pharmacokinetics #antibioticresistance #antibiotics #antimicrobialstewardship #antimicrobialresistance #clinicalmicrobiology #globalhealth #publichealth #pharmacology #superbugs #gramnegative

In business news, argenx reported preliminary financial results for the full-year 2023, including global net product sales (inclusive of both VYVGART® and VYVGART Hytrulo), and announced its strategic priorities for 2024. Highlights are: Reported $1.2 billion in preliminary* full-year 2023 global net product sales; Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024; Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN; Data from six Phase 2 proof-of-concept trials expected by end of 2024; Nominated four new pipeline candidates with IND filings expected by end of 2025. https://lnkd.in/ePcvcHYt

Exciting Updates from CPHI China 2024 As CPHI China 2024 concludes, heartfelt thanks go out to all involved - partners, sponsors, organizers, and participants. Your dedication and hard work ensured the event's success. Another successful year at CPHI - the leading global event uniting pharma professionals for over three decades! From fostering connections to inspiring partnerships, CPHI continues to champion innovation at the heart of the pharmaceutical industry. This year, our team had the privilege to attend the event held in the Shanghai China 2024. Our CEO  Dr. Santosh Joshi along with his team Mr. Sunil Bharti (Business Development Head) and Mr. Satyam Ghag, represented our company with enthusiasm and passion. They seized the opportunity to network, learn, and contribute valuable insights to the community. We believe in the power of collaboration and knowledge sharing. Our team not only gained valuable insights but also shared their own experiences, contributing to the collective growth of the industry. As we say goodbye to #CPHIChina 2024, We are now committed to staying connected with our industry peers. Let's continue to innovate, collaborate, and shape the future of pharma together! #CPHI #CPHIChina #China #pharma #Pharmaceuticals #clinical #clinicalreserch #Clinicaltrial #Clinical #pharmasource #drugs #drugsdevelopment #analysis #India #Indianpharma #medicine

💉 💊 Recently, Servier announced FDA approval of Tibsovo (ivosidenib) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). This is the fifth indication for Tibsovo across IDH1-mutated cancers, and the first and only approved targeted therapy for people diagnosed with R/R MDS within this molecularly defined subset, thereby solidifying its leadership in mutant IDH inhibition. Leveraging our Patent Analytics module, we have identified that Servier Pharmaceuticals LLC is the one of the top patent assignees treating MDS via targeting isocitrate dehydrogenase. 💡 GlobalData #Patent module delivers specialized expertise in the #pharmaceutical industry, harnessing our unique #data, #insights, and #analytics. Our tailored approach and deliverables empower you with comprehensive answers to your specific patent-related questions. To learn more about our Patent capabilities or to have a chat, just drop us an 📧 email at patents@globaldata.com or ☎ contact us here>>> https://lnkd.in/deGad__f and we will get in touch! #tibsovo #ivosidenib #myelodysplasticsyndromes #fdaapproval

I am speaking Wednesday, Apr 17 at 11:40 AM EST in the Pharmaceutical R&D Informatics program at Bio-IT World Conference & Expo. The Evolution of PiG Disco: From the Centralization of HLA Peptide in Groove Data through the Advancements of New Enhancements for Quicker Target Discovery/Validation Deciphering the composition of the human immunopeptidome is important to understand the immune system and to guide in the development of next-generation vaccines and immunotherapies against autoimmunity, infectious diseases, and cancers. Mass spectrometry is the only available technology to interrogate the immunopeptidome in an accurate manner, yet we had only had a rudimentary way of searching through all this data. Follow our journey in how we implemented a powerhouse application. https://lnkd.in/ephT7Bc4

Wishing you a Happy New Year filled with prosperity, good health, and the fulfillment of our shared mission to make a positive difference in the world. Cheers to a year of medical milestones and continued success!" #Happynewyear2024 #Kingsglobal #Biotech #pharmaceuticals #indiangenerics #pharmaceuticalindustry #pharmamanufacturing #makeinindia #cphi #arabhealth2024 #oncology #contractmanufacturing